MedTrace Logo

Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study

NCT02991131 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 108

Last updated 2019-10-02

No results posted yet for this study

Summary

This open-label, prospective, multi-center, non-interventional, observational, parallel cohort study intended to provide real life data on the treatment duration, effectiveness and safety of tedizolid and linezolid when treating ABSSSI hospitalized patients in a real practice setting.

Conditions

  • Skin Disease, Infectious

Interventions

DRUG

Tedizolid (Sivextro, BAY1192631)

Antibiotic

DRUG

Linezolid

Antibiotic

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-17
Primary Completion
2018-11-21
Completion
2018-11-21
FDA Drug
Yes

Countries

  • Mexico
  • Russia
  • Singapore

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02991131 on ClinicalTrials.gov